自体DC-CIK细胞联合化疗治疗晚期胃癌的回顾性研究

目的:评估自体DC-CIK细胞联合化疗用于晚期胃癌患者的疗效、生活质量及安全性.方法:收集2012年6月至2015年12月在兰州大学第一医院肿瘤内科住院并接受DC-CIK细胞联合化疗治疗的晚期胃癌患者70例为联合组.另外选取同期临床情况相似,仅进行化疗的晚期胃癌患者70例为对照组.观察两组的有效率、疾病控制率、无进展生存时间及总生存时间,评价其毒性反应发生情况,并分析两组患者治疗前后的生活质量改善情况.结果:联合组和对照组治疗的有效率分别为37.8％和29.5％ (P ＞0.05),疾病控制率为80.0％和59.1％ (P ＜0.05),无进展生存期为7.0和5.0个月(HR 0.62,95％ CI 0.41 ～0.92,P＜0.05),中位生存期为13.0个月和10.8个月(HR 0.68,95％CI 0.45 ～ 1.02,P＞0.05);与对照组相比,联合组化疗前后生活质量未见明显下降;未见DC-CIK细胞相关严重不良事件发生.结论:自体DC-CIK细胞联合化疗治疗晚期胃癌在有效率、疾病控制率、生存期及生活质量等方面获得了一定的收益,无严重不良事件发生.

Retrospective study on autologous DC-CIK cell combined with chemotherapy for the patients with advanced gastric cancer

Objective:To retrospectively evaluatethe efficacy, quality of life and safety of autologous DC-CIK cells in patients with advanced gastric cancer. Methods: Seventy patientswith advanced gastric cancer who received autologous DC-CIK immunotherapy plus chemotherapy, defined as combination group, were analyzed. Another seventy gastric cancer patients with similar clinical characteristics and received chemotherapy alone, defined as control group,were also selected. The response rate, survival, quality of life and toxicities were respectively analyzed for two groups. Results: In combination group and control group, the response rate was 37.8% versus 29.5% (P>0.05), disease control rate 80.0% versus 59.1% (P<0.05), progression-free survival 7.0 months versus 5.0 months (HR 0.62,95%CI 0.41-0.92, P<0.05) and overall survival 13.0 months versus 10.8 months (HR 0.68,95%CI 0.45-1.02, P>0.05). Compared to that in control group, the quality of life did not decrease obviously after chemotheray in combination group. No severe toxicity was observed after infusion of DC-CIK cells. Conclusion: DC-CIK immunotherapy in combination with chemotherapy demonstrated some clinical benefits, and no severe toxicity appeared in patients with advanced gastric cancer.